Clanotech's lead compound in development, CLT-28643, has recently been granted a European Patent by the European Patent Office.

STOCKHOLM – June 15, 2015. Clanotech AB, a company developing α5β1 integrin inhibiting products for ophthalmic use, announced that the European Patent Office recently granted the patent for its lead drug candidate CLT-28643.

"This patent further strengthens the IP positon of CLT-28643 and the further advance of CLT-28643 program as anti-fibrotic therapy in glaucoma surgery as primary indication. This together with the orphan drug designation, will shorten the future market approval processes and reinforce the potential market exclusivity for CLT-28643" said Patrizia Caldirola, CEO, Clanotech.

By inhibiting α5β1 integrin, CLT-28643 has been shown to have potent anti-fibrotic and anti-angiogenic properties and to be superior to current adjuvant therapy in an animal model of glaucoma surgery. Clanotech is now preparing for a phase II trial with CLT-28643 as an adjuvant to surgery in patients requiring trabeculectomy .

In 5 – 10% of glaucoma patients, the use of products that lower intraocular pressure is not enough to prevent further deterioration of glaucomatous field loss. In these cases, surgical intervention may be recommended. The most commonly used procedure is trabeculectomy, in which a new channel is formed to drain aqueous humour from the eye. Excessive scarring of the surgical area leads to failure in a high proportion of patients. To prevent this cytotoxic drugs like Mitomycin C are used. There is an unmet medical need for a product that can prevent scarring without the complications of cytotoxic drugs.

Clanotech AB is presenting at New York Venture Summit in June 23-24th New York.

For further information, please contact:
Patrizia Caldirola, CEO, Clanotech AB
Phone: +46 70 374 7179
e-mail: patrizia.caldirola@clanotech.com

TO THE EDITORS
About Clanotech AB
Clanotech is a Swedish discovery and development company active in ophthalmology. Clanotech's development strategy spans from niche indications with orphan drug opportunities such as developing safe and target specific anti-scarring treatment in glaucoma surgery techniques to therapeutic areas with high commercial potential such as wet Age Related Macular Degeneration, proliferative diabetic retinopathy, proliferative vitreoretinopathy, pterygium etc.. Clanotech's lead candidate is an inhibitor of the α5β1-integrin receptor which is present in fibroblast and on vascular endothelial cells. α5β1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery and in pathological angiogenesis

----------ENDS----------